Alkindi

Active substance: calcitriol
Strengths: 0.5 mg, 1 mg, 2 mg, 5 mg
Shelf life: long
Pack: 50 pcs
Indications: acute adrenal insufficiency, immediate-type allergic reactions, status asthmaticus, prevention and treatment of shock, myocardial infarction complicated by cardiogenic shock, thyrotoxic crisis, thyroiditis, congenital adrenal hyperplasia, hypercalcaemia due to tumour disease, short or additional therapy in the acute period of rheumatic diseases, collagen diseases, pemphigus, bullous dermatitis herpetiformis (Duhring’s disease), erythema multiforme bullosum, exfoliative dermatitis, mycosis fungoides, severe forms of psoriasis and seborrhoeic dermatitis, severe acute and chronic allergic and inflammatory processes involving the eyes, symptomatic sarcoidosis, Loeffler’s syndrome resistant to other types of therapy, berylliosis, focal or disseminated tuberculosis with concurrent antituberculosis chemotherapy, aspiration pneumonitis, idiopathic thrombocytopenic purpura in adults (i.v. only!), secondary thrombocytopenia in adults, acquired (autoimmune) haemolytic anaemia, erythroblastopenia, congenital (erythroid) hypoplastic anaemia, palliative therapy in adult leukaemias and lymphomas, in acute leukaemias in children, to enhance diuresis or to reduce proteinuria in nephrotic syndrome without uraemia, in nephrotic syndrome of the idiopathic type or in lupus erythematosus, in the critical stage of ulcerative colitis and regional regional enteritis (as systemic treatment), tuberculous meningitis with development of subarachnoid block or the threat thereof (in combination with antituberculosis chemotherapy), trichinosis involving the nervous system or myocardium, bronchial asthma, joint diseases